Literature DB >> 34542664

L-Theanine inhibits melanoma cell growth and migration via regulating expression of the clock gene BMAL1.

Ruyi Zhang1, Shuangning Zheng1, Zhen Guo1, Yanan Wang1, Guocui Yang1, Zhimin Yin2, Lan Luo3.   

Abstract

PURPOSE: L-Theanine is a unique non-protein amino acid found in green tea, which has been identified as a safe dietary supplement. It has been reported that L-theanine exerts various biological activities. In this study, we explored the anti-cancer effects of L-theanine on melanoma cells.
METHODS: A375, B16-F10, and PIG1 cell lines were used in the present study. EdU labeling, TUNEL and Annexin V/PI staining, wound-healing, and transwell migration assay were performed to detect the effects of L-theanine on melanoma cell proliferation, apoptosis, and migration. Brain and muscle Arnt-like protein 1 (BMAL1) was knocked down in melanoma cells to evaluate if L-theanine plays the anti-cancer role through regulating circadian rhythm of melanoma cells. The western blot, qRT-PCR, and dual luciferase assay were performed to explore the mechanism involved in the effects of L-theanine on melanoma cells.
RESULTS: L-Theanine apparently reduced the viability of melanoma cells. Further experiments showed that L-theanine attenuated the proliferation and migration, and promoted apoptosis of melanoma cells. L-Theanine significantly enhanced the expression of BMAL1, a clock gene in melanoma cells. Down-regulation of BMAL1 suppressed the anti-cancer effects of L-theanine on melanoma cells. Further experiments indicated that the p53 transcriptional activity raised by L-theanine was dependent on BMAL1 expression in melanoma cells.
CONCLUSION: L-Theanine exerts the anti-cancer effect on melanoma cells through attenuating the proliferation and migration, and promoting apoptosis of them, which is dependent on the regulation of the clock gene Bmal1 in melanoma cells.
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  BMAL1; Clock gene; L-Theanine; Melanoma; p53

Mesh:

Substances:

Year:  2021        PMID: 34542664     DOI: 10.1007/s00394-021-02677-y

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  51 in total

1.  BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management.

Authors:  Elisabeth Livingstone; Lisa Zimmer; Julia Vaubel; Dirk Schadendorf
Journal:  Chin Clin Oncol       Date:  2014-09

2.  Role of the CLOCK protein in liver detoxification.

Authors:  Mengjing Zhao; Huan Zhao; Jiangming Deng; Lianxia Guo; Baojian Wu
Journal:  Br J Pharmacol       Date:  2019-12-28       Impact factor: 8.739

Review 3.  Melanoma.

Authors:  Conor H O'Neill; Charles R Scoggins
Journal:  J Surg Oncol       Date:  2019-06-27       Impact factor: 3.454

Review 4.  Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers.

Authors:  Ossama Abbas; Daniel D Miller; Jag Bhawan
Journal:  Am J Dermatopathol       Date:  2014-05       Impact factor: 1.533

5.  Altered expression patterns of clock gene mRNAs and clock proteins in human skin tumors.

Authors:  Zsuzsanna Lengyel; Csenge Lovig; Siri Kommedal; Rita Keszthelyi; György Szekeres; Zita Battyáni; Valér Csernus; András Dávid Nagy
Journal:  Tumour Biol       Date:  2012-12-15

Review 6.  Chemotherapy for Melanoma.

Authors:  Melissa A Wilson; Lynn M Schuchter
Journal:  Cancer Treat Res       Date:  2016

Review 7.  The Circadian Clock and Human Health.

Authors:  Till Roenneberg; Martha Merrow
Journal:  Curr Biol       Date:  2016-05-23       Impact factor: 10.834

8.  Identification of a melanoma susceptibility locus and somatic mutation in TET2.

Authors:  Fengju Song; Christopher I Amos; Jeffrey E Lee; Christine G Lian; Shenying Fang; Hongliang Liu; Stuart MacGregor; Mark M Iles; Matthew H Law; Neal I Lindeman; Grant W Montgomery; David L Duffy; Anne E Cust; Mark A Jenkins; David C Whiteman; Richard F Kefford; Graham G Giles; Bruce K Armstrong; Joanne F Aitken; John L Hopper; Kevin M Brown; Nicholas G Martin; Graham J Mann; D Timothy Bishop; Julia A Newton Bishop; Peter Kraft; Abrar A Qureshi; Peter A Kanetsky; Nicholas K Hayward; David J Hunter; Qingyi Wei; Jiali Han
Journal:  Carcinogenesis       Date:  2014-06-30       Impact factor: 4.944

9.  A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells.

Authors:  Julia Klicks; Christoph Maßlo; Andreas Kluth; Rüdiger Rudolf; Mathias Hafner
Journal:  BMC Cancer       Date:  2019-04-29       Impact factor: 4.430

10.  Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.

Authors:  Brandilyn A Peters; Melissa Wilson; Una Moran; Anna Pavlick; Allison Izsak; Todd Wechter; Jeffrey S Weber; Iman Osman; Jiyoung Ahn
Journal:  Genome Med       Date:  2019-10-09       Impact factor: 11.117

View more
  1 in total

1.  A combined aging and immune prognostic signature predict prognosis and responsiveness to immunotherapy in melanoma.

Authors:  Wenchang Lv; YuanYuan Zhan; Yufang Tan; Yiping Wu; Hongbo Chen
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.